The Senate Finance
Committee has determined that the prices charged by Gilead for the Hepatitis C
drugs, Sovaldi and Harvoni, do not reflect the actual research or cost incurred
in producing the drugs and is officially accusing Gilead of placing profits
ahead of affordability and accessibility. In 2014, Medicare and Medicaid spent
more than $5 billion on Sovaldi and Harvoni. Gilead released a statement saying
that with available rebates and discounts the cost is actually less expensive
than that of prior treatments, and, additionally, the improved efficacy of
their drugs reduce the cost of future medical complications.
To read the full Reuters article click here.
No comments:
Post a Comment